Skip to content
lifestyle.faithfamilyamerica.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NetraMark Holdings Inc.
NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness
July 13, 2026
NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner
July 9, 2026
NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company
June 29, 2026
NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum
May 15, 2026
NetraMark Announces Change To Board Of Directors
May 7, 2026
NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI
May 4, 2026
NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026
April 30, 2026
NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset
March 25, 2026
NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer’s Trial at AD/PD Conference
March 19, 2026
NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data
March 11, 2026
1
2
Next Page
→